logo-loader
LON:STX

Shield Therapeutics PLC

Receive alerts
Market:
LON
Market Cap:
£216.8 m
Price
£1.85
Change
3.64%
52 weeks high
202.00
52 weeks low
27.00

In brief

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company’s clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

Insight

Research

Shield Therapeutics PLC: FDA approves broad label for Feraccru

Shield Therapeutics (LON:STX) reports it has achieved the best...

3 weeks ago
Deep dive

Shield Therapeutics primed for a busy year

Here we take a look under the hood of Shield Therapeutics

on 05/09/2019
Research

Shield Therapeutics PLC Heading for a US approval decision

Shield Therapeutics (LON:STX) is making excellent progress hav...

on 05/09/2019
Research

Shield Therapeutics PLC - Feraccru: a potential game changer in the treatment of iron deficiency anaemia

Feraccru is a unique, non-salt, formulation oral iron: strong ...

on 01/18/2019